• Penumbra received FDA clearance for its Lightning computer-assisted vacuum thrombectomy technology to treat deep vein thrombosis.
• The supporting BOLT-DVT trial showed complete or near-complete clot removal in 98% of patients, with a 3.1% major adverse event rate.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Penumbra Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: SF76163) on October 20, 2026, and is solely responsible for the information contained therein.